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Abstract
Healthcare acquired infections (HAI) pose a great threat in hospital settings and environ-
mental contamination can be attributed to the spread of these. De-contamination and, signif-
icantly, prevention of re-contamination of the environment could help in preventing/reducing
this threat. Goldshield (GS5) is a novel organosilane biocide marketed as a single applica-
tion product with residual biocidal activity. We tested the hypothesis that GS5 could provide
longer-term residual antimicrobial activity than existing disinfectants once applied to sur-
faces. Thus, the residual bactericidal properties of GS5, Actichlor and Distel against
repeated challenge with Staphylococcus aureus ATCC43300 were tested, and showed that
GS5 alone exhibited longer-term bactericidal activity for up to 6 days on 316I stainless steel
surfaces. Having established efficacy against S. aureus, we tested GS5 against common
healthcare acquired pathogens, and demonstrated that, on average, a 1 log10 bactericidal
effect was exhibited by GS5 treated surfaces, although biocidal activity varied depending
upon the surface type and the species of bacteria. The ability of GS5 to prevent Pseudomo-
nas aeruginosa biofilm formation was measured in standard microtitre plate assays, where
it had no significant effect on either biofilm formation or development. Taken together the
data suggests that GS5 treatment of surfaces may be a useful means to reducing bacterial
contamination in the context of infection control practices.
Introduction
Healthcare acquired infections (HAIs) are directly and indirectly responsible for increased
morbidity and mortality rates in hospitals worldwide. In Europe alone there are >4.5 million
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cases annually, which result in>37,000 deaths [1]. A further consequence is the financial bur-
den associated with these infections, measured in terms of increased length of patient stay,
decreased bed availability as a result and the extra cost of antibiotic therapy to treat the infec-
tion. In the USA alone the total annual expenditure on HAI is estimated to be in excess of $9.8
billion (£6–7 billion) [2], while in Europe a figure of over €7 billion (~£5.5 billion) has been
proposed [3]. As a consequence, there is increasing interest from industrial, research and
development and healthcare sectors in the development of viable and cost-effective alternative
methods of reducing HAI.
Common healthcare associated pathogens include Staphylococcus aureus (and predomi-
nantly Methicillin resistant Staphylococcus aureus (MRSA)), Vancomycin-resistant Enterococci
(VRE), Clostridium difficile, and Pseudomonas aeruginosa. Such microorganisms have been
shown to survive on inanimate surfaces for extended periods of time—for example S. aureus
has been shown to survive as long as 6 months [4,5] while Enterococci can survive as long as 4
months [6]. Clostridium difficile infections (CDI), the most common HAI type in Europe [7]
are attributed in part to the persistence of infectious spores on hospital surfaces for up to 5
months [5]. Bacteria capable of forming biofilms, such as P. aeruginosa and S. aureus, also sur-
vive and persist in the environment due to this ability, on top of any intrinsic resistance to anti-
microbials [8]. Thus vegetative cells, spores, or biofilms present a threat of infection and
indeed a recent report identified biofilm within water taps as the cause of a series of neonatal
P. aeruginosa infections [9].
Evidence of a direct correlation between environmental contamination and infection rates
exists [5,10,11,12] and microbial contamination of the environment has been shown to act as a
source of infection that is directly responsible for transmission of organisms to patients [12].
The most problematic areas tend to be high-touch points such as bed rails, door handles, table
top surfaces, bedding (mattress), television controls and staff uniforms [13]. Such contami-
nated surfaces act as a source of direct to patient, and indirect—via healthcare workers/instru-
ments—spread to patients [5,14]. As long as these organisms persist in a hospital or healthcare
facility environment they remain a source of infection and therefore, hospitals have imple-
mented revised and improved infection control practices in order to reduce and ideally eradi-
cate environmental microbial contamination. This is achieved primarily by the use of
disinfectants and detergents, although the precise disinfectant used will be dependent on mul-
tiple factors. For example, areas of high risk such as operating theatres will require multiple
cleans per day, whereas patient waiting rooms may be cleaned only once per day. The choice
of disinfectant agent is also multifactorial: body fluid spillages will normally require higher
level disinfectants than those used in routine cleaning. As a result, hospitals will use a variety
of products including ethyl alcohol in hand rubs and gels, Quaternary ammonium compounds
(QACs), chlorine-releasing agents and peroxygen sterilants [15]. Nonetheless, current cleaning
methods have in several instances been shown to be ineffective. Work by French et al. [11]
showed that 74% of sites in a London hospital were MRSA positive and when these same sites
were retested post-cleaning, all were still contaminated [11]. Recurrence of contamination on
surfaces, post disinfection, is therefore a significant issue and this is especially true of high-
touch surfaces [16]. Given the available evidence for the ineffectiveness of cleaning and rapid
recontamination of surfaces, there is currently much interest in alternative approaches to the
problem. The development of intrinsically anti-microbial surfaces that incorporate a variety of
agents to kill microbes may be considered a useful strategy. Alternatively, the use of specialised
agents that are capable of preventing surface contamination, or that exhibit a residual antimi-
crobial activity post-disinfection, could be employed, and such products have recently been
highlighted as of potential utility in the healthcare setting [17].
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One such antimicrobial product is Goldshield, distributed by Goldshield Technologies Ltd.
[GS hereinafter]. This is a patented, water soluble organosilane, coupled with a quaternary
ammonium compound that is designed to coat surfaces with a protective antimicrobial layer
to prevent microbial contamination. The product was originally designed at Emory University,
USA and is the subject of three US patents (patent nos. US5,959,014, US6,221,944, and
US6,632,805). In this paper we report the bactericidal and anti-biofilm of GS5 technology
against 11 common healthcare associated pathogens.
Materials and methods
Chemicals, glassware and media
All glassware was sterilised by soaking overnight in 1% Virkon (Antec, UK) and steam steri-
lised in an autoclave prior to use. All culture media (Oxoid, UK) was prepared as per the man-
ufacturer’s instructions. Phosphate Buffered Saline (Oxoid, UK) was prepared in deionised
water and steam sterilised in an autoclave prior to use. Two model surfaces were used. 316l
Steel (Aalco, UK) or Formica were cut into 2cm×2cm samples, autoclaved (121˚C for 15 min)
and stored in a sealed sterile container prior to use.
Microorganisms
Ten bacterial species were obtained from either the American Type Culture Collection
(ATCC) or the Leibniz-Institute DSMZ German Collection of Microorganisms and Cell Cul-
tures (DSMZ). Bacteria included Escherichia coli ATCC25922, Klebsiella pneumoniae
DSM16358, Mycobacterium smegmatis DSM43469, Pseudomonas aeruginosa DSM3227, Staph-
ylococcus aureus (MRSA) ATCC43300, Staphylococcus aureus (non-MRSA) DSM20231, Staph-
ylococcus epidermidis DSM28319 (all cultured at 37˚C using Nutrient broth/agar),
Enterococcus faecalis DSM12956 (37˚C using Tryptone soya broth/agar), Burkholderia multi-
vorans DSM13243 (28˚C using Nutrient broth/agar) and Acinetobacter baumannii DSM30008
(30˚C using Nutrient broth and agar). These were chosen as representative organisms of the
type causing HAIs commonly seen in hospitals [18] and included Gram positive organisms,
Gram negative organisms and Mycobacteria. Mycobacterium smegmatis was used as it is a fast-
ing-growing model Mycobacterium species [19]. Organisms were stored on Cryobeads (Tech-
nical Service Consultants Ltd, UK) at -80˚C and recovered in suitable media when required.
Disinfectant agents
Three disinfectant agents used (GS5, Actichlor and Distel) are classed bactericidal surface dis-
infectants. The characteristics of these antimicrobial agents are summarised in Table 1. Agents
were acquired as full strength concentrate and working stock concentrations were prepared by
dilution with deionised water as per the respective manufacturer’s instructions.
Direct bactericidal assessment of GS5
To determine directly the bactericidal activity of GS5, a suspension contact time assay was
completed; varying concentrations of GS5 were mixed with S. aureus ATCC43300, followed by
recovery and enumeration of viable cells to determine Log10 reduction. 0% (sterile water),
0.25% (v/v), 0.5% (v/v) and 1% (v/v) GS5 dilutions were prepared using sterile water as diluent.
A 10 μl aliquot of mid-log S. aureus ATCC43300 was mixed with each of the GS5 concentra-
tions and left to stand at room temperature for 5 min. Bacteria were enumerated by dilution
plating 0.1ml aliquots onto Nutrient agar in duplicates and incubating at 37˚C for 24 h fol-
lowed by direct colony counts. Three biologically independent experiments were performed.
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Residual surface activity of disinfectants
To investigate the residual activity of surface disinfectants a protocol was developed from the
EN13697 standard and the work of Baxa et al. [20]. Staphylococcus aureus ATCC43300
(MRSA) and 316l Steel were used. The 316l Steel surface samples were sprayed with either
GS5, Actichlor, Distel or sterile water (no treatment control) using a hand spray. The test sur-
faces were left to dry in the sterile environment of a category 2 cabinet (Biomat). S. aureus
ATCC43300 was grown to mid log phase of growth (OD600 = ~0.48) and diluted 1/100 using
sterile PBS (Oxoid, UK). A total of 100 μl of this was added (in 10 μl droplets) to technical trip-
licate examples of each surface. Bacteria were left on the surfaces for 45 min, and then viable
cells recovered in 10 ml of sterile PBS by vortexing for 2 min. Bacteria were enumerated by
plating dilution series in duplicate on Nutrient Agar and incubating at 37˚C for 24 h followed
by direct colony counts [20]. Following recovery of bacteria from the surfaces each surface was
individually washed using sterile PBS, air dried and stored in a sterile storage box. These sur-
faces were then re-challenged with S. aureus ATCC43300 as above. This re-challenge was
repeated at 3-day intervals over 15 days. Three biologically independent experiments were
performed.
GS5 bactericidal surface testing
A selection of 10 different bacteria, representative of important HAI, were individually tested
on 316l Steel and Formica. Testing was performed once to determine the maximum antimi-
crobial effect for a freshly treated surface. The protocol was as described above, but without re-
challenge and only the activity of GS5 was assessed.
Assessment of GS5 efficacy against biofilms
Pseudomonas aeruginosa DSM3227 biofilms were grown in 24-well microtiter plates (4 wells
per treatment) and these were stained with 0.1% crystal violet to assess the extent of biofilm
growth according to established methods [21,22,23]. To determine efficacy of GS5 against bio-
film, Thermo Scientific™ Nunc™ Cell-Culture Treated Multidishes, (Thermo Scientific, UK)
were pre-treated with either 5% GS5 or sterile water (untreated): wells were soaked with 1 ml
of agent for 10 min following which treatment agents were aspirated and plates left to dry in a
sterile environment (Biomat category 2 cabinet). An overnight culture of P. aeruginosa
DSM3227 was diluted 1/100 (using sterile nutrient broth) and microtitre plate wells inoculated
with a 1 ml aliquot following which the plates were incubated aerobically at 37˚C. At defined
time points (8 h, 12 h, 24 h, 48 h, 72 h and 96 h) biofilm production was assessed. The medium
containing planktonic cells was removed and wells stained with 1.5 ml of 0.1% Crystal Violet
(Sigma-Aldrich, UK) for 10 min at room temperature. Unbound crystal violet (Sigma-Aldrich,
Table 1. Antimicrobial products tested.
Agent Type Active ingredient Concentration
used*
Goldshield5 Organosilane coupled with Quaternary Ammonium
Compound (siQAC)
Trihydroxysilylpropyldimethyloctadecyl ammonium
chloride
1:20 dilution
Actichlor Chlorine-based disinfectant Sodium dichloroisocyanurate 1:10 dilution
Distel Quaternary Ammonium Compound Tertiary alylamine and quaternary ammonium
compounds
1:100 dilution
* as per manufacturer’s instructions.
https://doi.org/10.1371/journal.pone.0182624.t001
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UK) was removed and stained wells washed twice with 2ml sterile PBS following which bound
crystal violet was solubilised using 1.5 ml of 30% Acetic Acid (Thermo Scientific, UK) for 30
min at room temperature. A 1 ml aliquot from each well was transferred to a fresh 24-well
microtiter plate and the absorbance of the crystal violet measured at 570nm using a FLUROs-
tar Omega plate reader (BMG LABTECH, Europe). Each experiment was repeated on three
separate occasions.
Assessment of GS5 effects on bacterial viability in biofilm
Bacterial viability in biofilms was assessed using the BacLight Live/Dead bacterial viability kit
(L-7007; Molecular Probes, Eugene, OR) [24,25]. With Baclight, live cells stain green and
dead/damaged cells stain red. A stock solution was prepared by mixing 4 μl of component A
(1.67 mM Syto9 plus 1.67 mM propidium iodide), 6 μl of component B (1.67 mM syto9 plus
18.3 mM propidium iodide) and 1ml of sterile water as described by Bauer et al. [25]. P. aerugi-
nosa DSM3227 biofilm was grown in 4-well Nunc™ Lab-Tek™ II Chamber Slide™ Systems
(Thermo Scientific, UK) pre-treated with either 5% GS5 or sterile deionised water. Slides were
inoculated with 1 ml of a 1/100 dilution of overnight culture of P. aeruginosa and incubated
aerobically for 24 h and 48 h at 37˚C. At each time point excess media and planktonic cells
were removed and the wells washed with sterile PBS followed by staining with 200 μl BacLight
mix and 100 μl of sterile water. Stained slides were incubated in the dark at room temperature
for 30 min following which the wells were then washed with sterile PBS and viewed using ×100
oil immersion on a Nikon ECLIPSE E400 (Nikon) microscope utilising a dual-band emission
filter (450–490 nm/510–560 nm). Images were generated using NIS-Elements BR (Nikon) soft-
ware version 3.22.09. Image J software was used to generate composite (red/green) images of
the baclight stained biofilms.
Statistical analysis
For bactericidal testing, log10 changes in viable bacterial numbers, compared to untreated con-
trols was determined. The equation Log Reduction LR = log10 (Ncontrol)–log10 (Ntreated) was
used where Ncontrol is total recovery of untreated bacteria and Ntreated is total recovery of treated
bacteria. Data was imported to Graphpad Prism 6.01 and charts constructed. Statistical analy-
sis was completed using SPSS v22.
Results
Direct bactericidal assessment of GS5
We firstly wished to determine if GS5 was effective against bacteria in solution, prior to surface
testing. We hypothesised that a solution of GS5 at working concentration would exhibit a bac-
tericidal effect against a suspension of bacteria. The direct antibacterial effects of GS5 against
S. aureus ATCC43300 was assessed using a suspension assay. S. aureus ATCC43300 was chal-
lenged with increasing concentrations of GS5 to quantify bactericidal activity. GS5 exhibited
bactericidal actions at all concentrations after 5min contact time as shown in Fig 1 (0.25% =
4.96 Log10 reduction; 0.5% = 5.6 Log10 reduction; 1% = 6 Log10 reduction (complete kill). Sub-
sequent testing was completed at 5% as per manufacturer’s instructions.
Residual activity of surface disinfectants
GS5 is reported to form covalent bonds with surfaces, thereby leaving a nanoscale antimicro-
bial coating which kills microbes that encounter that surface. This, it is claimed, makes GS5 a
more effective product due to its residual antimicrobial activity compared to other
Evaluation of a novel biocide against healthcare acquired pathogens and P. aeruginosa biofilm
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disinfectants. We designed an experiment to test this hypothesis by determining the residual
antimicrobial effect of GS5, Actichlor and Distel. The bactericidal activity of the three surface
disinfectant agents was tested against S. aureus ATCC43300 on 316l Steel (Aalco, UK) and
residual activity was assessed over 15 days at 3 day intervals. All three products exhibit bacteri-
cidal activity on day 0 (Actichlor = 3.75Log10 reduction; Distel = 0.54 Log10reduction;
GS5 = 1.16 Log10 reduction). Following subsequent re-challenge of treated surfaces with S.
aureus ATCC43300 only GS5 showed significant residual bactericidal activity; this residual
activity exerted by GS5 was evident for 6 days (Day 3 GS5 = 0.53 Log10 reduction; Day 6
GS5 = 0.26 Log10 reduction; Fig 2). For subsequent testing of the GS5 product, the maximum
effect time point (day 0) was used.
GS5 bactericidal surface testing
Baxa et al. [20] suggested that GS5 exhibited variable effect against different bacterial species.
We therefore tested GS5 against a range of healthcare acquired infection microorganisms on
316l Steel or Formica to determine bactericidal effect. As hypothesised, GS5 treated surfaces
did indeed exhibit a bactericidal effect against all ten tested microorganisms, and this effect
was observed on both Formica and steel. The largest bactericidal effect was observed with
Staphylococcus strains where a>1 log10 reduction was observed on 316l Steel (S. aureus
ATCC43300 = 1.21 Log10 reduction; S. epidermidis DSM28319 = 1.06 Log10reduction)
(Table 2). On Formica, however, the GS5 product exhibited a lower bactericidal effect
(<0.5 = Log10reduction) against both Staphylococcus organisms. The average Log10 reduction
Fig 1. S. aureus ATCC43300 survival following suspension test using GS5. ~2×106 cfu/ml of S. aureus
ATCC43300 was challenged with increasing concentrations of GS5. Data represents mean +/- SD of three
independent experiments. Statistical analysis by independent T-tests versus Untreated (0%) controls (* =
p<0.05, ** = p<0.005, *** = p<0.001).
https://doi.org/10.1371/journal.pone.0182624.g001
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on steel surfaces for all bacteria tested was 0.6, whereas the average Log10 reduction on For-
mica was 0.45.
Effect of GS5 on bacterial biofilm formation
Walker et al. [9] have demonstrated that biofilm contamination can contribute significantly to
outbreaks of healthcare acquired infections. Given the efficacy of GS5 against a range of HAI
microbes, we hypothesised that a GS5-treated surface would impede the development of bacte-
rial biofilms. P. aeruginosa is a well characterised biofilm former [26], and therefore we pre-
treated plastic microtitre plate surfaces with GS5 and assessed the development of P. aerugi-
nosa DSM3227 biofilms. The crystal violet staining method provides a quantitative measure of
biofilm development/biomass and somewhat unexpectedly our data revealed that GS5 did not
appear to inhibit the development of P. aeruginosa DSM3227 biofilm in plastic microtiter
plates (Fig 3). Having observed that P. aeruginosa DSM3227 biofilm development was
Fig 2. Comparison of residual antimicrobial effects of GS5, Actichlor and Distel on steel surface
loaded with Staphylococcus aureus ATCC43300. GS5 exhibited prolonged antibacterial activity (6 days)
whereas Actichlor and Distel showed no antibacterial activity after day 0. Results are representative of three
independent experiments (n = 3; mean+/- SD plotted). Statistical analysis using One way ANOVA and
Dunnett’s T-test versus Untreated control (* = p<0.05, ** = p<0.005, *** = p<0.001).■ = Goldshield;● =
Untreated control;  = Actichlor; □ = Distel.
https://doi.org/10.1371/journal.pone.0182624.g002
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apparently unaffected, we assessed bacterial viability within the biofilms using the well-estab-
lished BacLight staining method. This analysis suggested that a proportion of the bacterial cells
were damaged or rendered non-viable when grown on GS5 treated surfaces, but that, critically,
a sufficient number of viable/undamaged cells remained (Fig 4) which, we hypothesise are
responsible for subsequent biofilm development.
Discussion
Only a single published report exists which details the effects of GS5 used as a surface biocide.
GS5 is reported to exert its antimicrobial effect via bonding of the silane end of the molecule to
surfaces, following which microbes are drawn onto the hydrocarbon chain. The resultant
puncturing of cell membranes and denaturation of proteins is proposed as the cause of cell
death [20]. As a covalent bond is formed with the surface it is hypothesised that this mode of
action is prolonged creating a ‘bactericidal surface’.
When we tested the prolonged activity GS5 exhibited bactericidal activity for 6 days (0.26
log10 reduction) whereas the other surface disinfectants tested showed no activity beyond day
0 (Fig 1). In comparison with previous residual testing of the GS5 product by Baxa et al. [20],
which was completed on fabric swatches rather than on hard surfaces, we observed that resid-
ual antimicrobial activity of GS5 was lower (6 days rather than 14 days) [20]. However, the
residual antibacterial effect decreased over time to a<1 log10 reduction in bacterial numbers,
suggesting that GS5 would need regular reapplication and would not be sufficient as a surface
disinfectant alone.
Table 2. Log10 reductions obtained on GS5 treated surfaces challenged with a variety of microbes.
Organism Surface Log10 Untreated ± SD Log10 Treated ± SD Log10 change p-value
Acinetobacter baumannii DSM30008 Steel 4.82 ±0.36 4.49 ±0.62 0.33* 0.0138
Formica 4.25 ±0.04 3.67 ±0.29 0.58*** <0.001
Burkholderia multivorans DSM13243 Steel 3.90 ±0.14 3.62 ±0.17 0.28*** <0.001
Formica 3.94 ±0.05 3.41 ±0.24 0.53** 0.0011
Enterococcus faecalis DSM12956 Steel 5.27 ±0.3 4.8 ±0.08 0.47 0.0623
Formica 5.15 ±0.13 4.86 ±0.03 0.29** 0.0016
Escherichia coli ATCC25922 Steel 5.57±0.28 5.32 ±0.33 0.25** 0.0018
Formica 5.54 ±0.09 5.22 ±0.02 0.32*** <0.001
Klebsiella pneumoniae DSM16358 Steel 4.30±0.27 3.54 ±0.33 0.76* 0.0135
Formica 3.94 ±0.05 3.41 ±0.24 0.53** 0.0011
Mycobacterium smegmatis DSM43469 Steel 4.06 ±0.22 3.46 ±0.45 0.6*** <0.001
Formica 5.83 ±0.43 5.16 ±0.44 0.67** 0.0026
Pseudomonas aeruginosa DSM3227 Steel 5.09±0.04 4.66±0.29 0.43** 0.0017
Formica 5.15±0.1 4.63±0.12 0.52*** <0.001
Staphylococcus aureus (MRSA) ATCC43300 Steel 4.19 ±0.13 2.99 ±0.58 1.2*** <0.001
Formica 5.04 ±0.03 4.68 ±0.08 0.36*** <0.001
Staphylococcus aureus (non-MRSA) DSM20231 Steel 4.57±0.22 3.48±0.27 1.09*** <0.001
Formica 5.02±0.23 3.94±0.35 1.08* 0.0089
Staphylococcus epidermidis DSM28319 Steel 3.95 ±0.04 2.88 ±0.05 1.07** 0.0047
Formica 5.25 ±0.19 4.94 ±0.25 0.31*** <0.001
Results are representative of three independent experiments (n = 3; mean+/- SD). p value calculated using paired T-Test (* = p<0.05, ** = p<0.005, *** =
p<0.001).
https://doi.org/10.1371/journal.pone.0182624.t002
Evaluation of a novel biocide against healthcare acquired pathogens and P. aeruginosa biofilm
PLOS ONE | https://doi.org/10.1371/journal.pone.0182624 August 7, 2017 8 / 13
GS5 treated surfaces exhibited bactericidal activity which varied in effectiveness between
surface type and bacterial species (Table 1). Thus, bacterial species challenged, in addition to
surface type/properties, appears to have a significant influence on the performance of the GS5
product. Surface hydrophobicity, charge and roughness have all been reported as important
with respect to performance of biocides [12]. Indeed, variations in the response of bacterial
species to disinfectants is evident in the literature with disparate log10 reductions and widely
varying minimum inhibitory concentrations (MICs); biocidal resistance is also evident
[20,27]. GS5 is said to not induce resistance in microorganisms as a result of its physical mode
of action, reported as membrane disruption and protein denaturation. We noted differences
between the results of our current work and data reported by Baxa et al. [20] who also tested S.
aureus, E. coli and P. aeruginosa on steel and Formica. The work of Baxa et al. [20] suggested
Fig 3. Biofilm development following pre-treatment with GS5. Pseudomonas aeruginosa DSM3227
biofilm biomass was assessed by crystal violet staining at various time points and data presented represents
mean +/- SD of three independent experiments. Statistical analysis by independent T-tests versus Untreated
controls (* = p<0.05, ** = p<0.005, *** = p<0.001). Grey columns representative of pre-treated samples;
black bars representative of untreated controls.
https://doi.org/10.1371/journal.pone.0182624.g003
Evaluation of a novel biocide against healthcare acquired pathogens and P. aeruginosa biofilm
PLOS ONE | https://doi.org/10.1371/journal.pone.0182624 August 7, 2017 9 / 13
that GS5 had greater efficacy against E. coli and P. aeruginosa, however this observation could
be a result of differing surface properties across different types of Steel and Formica used.
However, like Baxa et al. [20], we have shown that the performance of GS5 against different
bacterial species varies considerably, which indicates that the specific type of microbial con-
taminant will be of greater influence on the effectiveness of GS5, than the actual surface on
which it is used.
The ability of HCAI pathogens to adhere, via specific surface proteins to a range of sub-
strates likely to be found in healthcare settings, including polystyrene, has been reported [28].
While biofilms that develop on medical devices such as catheters, chest tubes, prosthetic joints
etc. are of concern [29], such medical devices were not the focus of our work. Beyond medical
devices, on which biofilms most certainly develop, the contamination of any surface with bac-
teria in a matrix containing nutrients, will potentially enable development of biofilm. Hospital
water systems, from storage to taps, allow biofilm formation and such contamination has been
directly linked to adverse health outcomes [9].
Experiments in which plastic surfaces were pre-treated for 10 min with GS5 showed that
there was no significant inhibitory effect against P. aeruginosa biofilm formation (Fig 3). It is
well documented that biofilms exhibit increased resistance to antimicrobials and disinfectants,
mainly due to the inability of these molecules to penetrate the biofilm [27]. Given that the
GS5-treated plate surfaces would be expected to possess antimicrobial activity, we then consid-
ered the viability of cells within developing biofilms. Using BacLight, we observed an initial
apparent bactericidal effect on P. aeruginosa DSM3227 cells (Fig 4c) as evidenced by a
Fig 4. BacLight staining of P. aeruginosa DSM3227 biofilm at 24 h and 48 h. Live cells appear green and dead/damaged cells appear
red. Images A and B show development of extensive biofilm on untreated surfaces. Image C shows biofilm development on GS5 treated
surface with a greater proportion of dead/damaged cells. Image D shows GS5 treated surface biofilm at 48 h: biofilm development and cell
viability is similar to the untreated control. Images were obtained ×100 magnification (oil immersion) on a Nikon ECLIPSE E400 (Nikon)
microscope utilising a dual-band emission filter (450–490 nm/510–560 nm) and NIS-Elements BR (Nikon) software; composite (red/green)
images generated using Image J software. Scale bar = 10 μm. Brightness values were generated for each panel (fig 4 a/b/c/d) using ‘imageJ
colour histogram analysis’ software which converts RBG pixels to brightness values (V = (R+G+B)/3). These red/green brightness values
are presented as bar charts to the right of the micrographs.
https://doi.org/10.1371/journal.pone.0182624.g004
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reduction in biofilm coverage and increased numbers of red stained, damaged, cells at 24 h.
This did not translate however, into reduced biofilm formation as measured by crystal violet
staining, and indeed later 48 h samples (Fig 4D) showed a well-developed biofilm containing
viable cells, similar to that observed in the untreated control (Fig 4B) It is likely, therefore, that
residual viable cells maintain the ability to form biofilm and we hypothesise that the cells that
are initially damaged by GS5 could actually promote biofilm formation: it has been suggested
that dead bacterial cell constituents could comprise a key component of the biofilm or indeed
even enhance adhesion and stability of cells, thereby allowing biofilm development [30]. Our
data, taken together suggest that GS5 treatment will not significantly inhibit biofilm
formation.
Conclusion
Current NHS Infection control practices require that when choosing disinfectants, a 4–5 Log10
reduction is required in viable vegetative bacterial cells within a contact/drying time of 10 min,
in addition to a spore reduction of 3 Log10 within the same period. When tested directly on a
suspension of bacterial cells, GS5 achieved a more than 4 Log10 reduction with a 5 min contact
time however the residual surface active antimicrobial activity of GS5 was much less, at
approximately 1 Log10 reduction in bacterial numbers. The surface protective effect of GS5
remained for a further 3–6 days without reapplication of the product, however we noted a
diminution of the measured Log10 reductions over time to a level which was much lower than
that required for use in infection control.
Bacteria can form biofilm on surfaces allowing prolonged survival and increased resistance
to biocides. Considering the GS5 mode of action we hypothesised a regime where GS5 could
be utilised to prevent biofilm formation on surfaces subsequently reducing risk of infection.
However GS5 has been shown to possess limited anti-biofilm properties as biofilm production
is not impeded on GS5 coated surfaces.
Within the NHS, certain disinfectants (for example, DifficilS) routinely achieve 4 Log10
reductions in both vegetative cell and spore numbers within 3–5 min however control of infec-
tion is only achievable in practice by using these products in intensive cleaning up to twice daily
in a rolling programme of disinfection. Thus, on the basis of the data generated in this work, it
appears unlikely, despite modest reductions in bacterial cell viability and evidence for a short
lived residual effect, that GS5 would replace current infection control products such as DifficilS
or Actichlor in reducing the transmission of HAI pathogens within hospitals and care settings.
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